Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Cancer is one of the leading causes of death worldwide. Conventional cancer therapies
mainly focus on mass cell killing without high specificity and often cause severe side effects …

Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant
treatment after surgery. First-line treatment with these drugs is generally used in the patients …

Somatostatin is an endogeneous cyclic tetradecapeptide hormone that exerts multiple
biological activities via five ubiquitously distributed receptor subtypes. Classified as a broad …

Abstract Because 1, 25 dihydroxyvitamin D3 (1, 25 (OH) 2D3) is known to activate the
biosynthesis of numerous proteins in various tissues, experiments were undertaken to …

Somatotropin-release inhibitory factor (SRIF) is a major regulator of pituitary function, mostly
inhibiting hormone secretion and to a lesser extent pituitary cell growth. Five SRIF receptor …

Acromegaly is a chronic disease with increased morbidity and mortality, where usually
multiple treatment modalities are used. The somatostatin analogs (SSAs) are the mainstay of …

Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess
growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like …

Octreotide remains 40 years after its development a drug, which is commonly used in the
treatment of acromegaly and GEP-NETs. Very little innovation that competes with this drug …